Clinical trial designs for cytostatic agents: Are new approaches needed?

Journal of Clinical Oncology

Volumn 19, Issue 1, 2001, Pages 265-272

  Korn, E L ^a   Arbuck, S G ^a   Pluda, J M ^a   Simon, R ^a   Kaplan, R S ^a   Christian, M C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSTATIC AGENT; CYTOTOXIC AGENT;

CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG RESEARCH; GROWTH INHIBITION; HUMAN; INFORMATION PROCESSING; MAXIMUM TOLERATED DOSE; METHODOLOGY; POPULATION; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TUMOR GROWTH; VALIDATION PROCESS;

EID: 0035154256     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.1.265     Document Type: Review

References (33)

1. Antiangiogenesis for cancer therapy
2. Matrix metalloproteinase inhibitors: Present achievements and future prospects
3. There are no bad anticancer agents, only bad clinical trial designs: Twenty First Richard and Hinda Rosenthal Foundation Award Lecture
4. Anticancer agents targeting signaling molecules and cancer cell environment: Challenges for drug development?
5. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
6. Antiintegrin v3 blocks human breast cancer growth and angiogenesis in human skin
7. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
8. New statistical designs for clinical trials of immunomodulating agents
9. Combined analysis of studies of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies
10. 6-benzylguanine for patients undergoing surgery for malignant glioma
11. Interferon-mediated downregulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule
12. Some practical improvements in the continual reassessment method for phase I studies
13. Accelerated titration designs for phase I clinical trials in oncology
14. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advance lung cancer
15. Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors
16. Comparison of preclinical efficacy and associated plasma concentrations of AG3340, a matrix metalloprotease (MMP) inhibitor, with plasma concentrations achieved clinically
17. Phase I study of the metalloproteinase inhibitor Bayer 12-9566
18. One sample multiple testing procedure for phase II clinical trials
19. Optimal two-stage designs for phase II clinical trials
20. Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism
21. Phase II trial of flavopiridol in metastatic colorectal cancer: Preliminary results
22. A design alternative for two-stage, phase II, multicenter cancer clinical trials
23. Multinomial phase II cancer trials incorporating response and early progression
24. A phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high-grade gliomas
25. Sample size considerations for studies comparing survival curves using historical controls
26. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas
27. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
28. Principles of cancer management: Chemotherapy
29. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue
30. Randomized phase II clinical trials
31. Stopping when the experimental regimen does not appear to help
32. Randomized discontinuation trials: Utility and efficiency
33. Threats to the validity of clinical trials employing enrichment strategies for sample selection